Infectious Disease Therapeutics Market: Market Size & Forecast 2026

The infectious disease therapeutics market covers pharmaceutical treatments targeting a broad range of pathogens, including human immunodeficiency virus (HIV), tuberculosis, hepatitis, and respiratory infections such as COVID-19. With a 2025 estimated value of $139.6 billion and a 6.5% annual growth trajectory, the market reflects sustained global demand for effective therapeutic interventions. Public health initiatives and regulatory approvals for novel treatments continue to expand market access, particularly in emerging economies.

• •Antivirals represent the largest treatment category, driven by HIV, hepatitis, and emerging viral infections.
• •The COVID-19 pandemic accelerated regulatory pathways and investment in broad-spectrum antiviral development.
• •Diagnostic advances in antibody testing and pathogen identification support targeted therapeutic strategies.

Growing antimicrobial resistance (AMR) remains a primary catalyst for market expansion, as drug-resistant bacterial and fungal infections necessitate the development of new therapeutic classes. Rising global prevalence of chronic infectious diseases, combined with improved healthcare access in low- and middle-income countries, is boosting treatment demand. Ongoing vaccine development programs and governmental public health preparedness initiatives further fuel investment in the sector.

• •The World Health Organization has identified AMR as a leading global health threat, spurring R&D spending on next-generation antibiotics.
• •Expanding immunization programs and novel mRNA vaccine platforms are broadening the preventive therapeutics segment.
• •Increasing incidence of chronic infectious conditions in aging populations drives long-term demand for maintenance therapies.

The market is segmented by drug class, antivirals, antibiotics, vaccines, antifungals, and antiparasitics, with antivirals accounting for the largest revenue share due to the persistent global HIV burden and hepatitis treatment demand. Geographically, North America leads in market size supported by advanced healthcare infrastructure and high pharmaceutical R&D expenditure, while Asia-Pacific is the fastest-growing region owing to its large population base and improving healthcare access. Europe holds a stable market position through strong regulatory frameworks and universal healthcare coverage.

• •North America: dominant market share driven by high treatment adoption, favorable regulatory pathways, and significant R&D investment.
• •Asia-Pacific: fastest-growing region, fueled by population size, rising healthcare spending, and expanding access to modern therapeutics.
• •Antiviral therapies constitute the leading segment, with HIV and hepatitis treatments representing substantial portions of global sales.

What are the recent trends and outlook?

Advances in genomic medicine, CRISPR-based diagnostics, and mRNA technology are reshaping how infectious diseases are detected and treated, creating new product opportunities. Regulatory agencies are streamlining review processes for breakthrough antimicrobial therapies, which could shorten time-to-market for novel treatments. Looking ahead, the convergence of digital health tools, AI-assisted drug discovery, and increased government funding positions the infectious disease therapeutics market for sustained growth well beyond 2025.

• •mRNA platform technologies, accelerated by COVID-19 vaccine success, are being applied to influenza, RSV, and other viral targets.
• •Artificial intelligence and computational biology are increasingly used to identify and optimize novel antimicrobial compounds.
• •Government initiatives such as the U.S. Biomedical Advanced Research and Development Authority (BARDA) programs are de-risking development and supporting market expansion.